Health Care Roundup: Market Talk
A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 5, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.
Siemens Healthineers initiated the formal separation of its diagnostics division, which will operate as Olyrian Diagnostics and become a standalone entity by mid-2028. The company also announced it will shorten its name to Healthineers, a move RBC Capital Markets suggests will alleviate concerns regarding Siemens licensing fees. Despite these positive developments, the analyst notes the process will incur over 200 million euros in stranded costs, which the firm intends to offset through a new savings program. Healthineers shares declined 1.9% following the announcement.
Background
- Novo Nordisk reported third-quarter results that exceeded expectations, with Wegovy pill sales reaching 5.4 billion Danish kroner, a figure 17% higher than analyst forecasts.
- Bayer executives stated during an earnings call that a decision on the approval of its proposed Roundup litigation settlement is expected before Christmas.
- Lonza Group acquired a U.S. contract-drug manufacturing business from Merck KGaA, a deal RBC Capital Markets estimates could generate approximately 500 million Swiss francs in revenue at peak utilization.
- Hikma Pharmaceuticals maintained its full-year sales guidance, with stronger branded-product revenue offsetting weaker performance in its injectables business.
Read the full article at wsj.com
More from Thursday, November 5:
Write a comment